Adenosine A2A Antagonists in Parkinson’s Disease: What’s Next?

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

(2011) A. F. Ramlackhansingh et al.   NEUROLOGY

Past, Present, and Future of the Pathophysiological Model of the Basal Ganglia

(2011) José A. Obeso et al.   Frontiers in Neuroanatomy

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

(2010) Robert A. Hodgson et al.   EXPERIMENTAL NEUROLOGY

Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease

(2010) K. J. Black et al.   JOURNAL OF NEUROSCIENCE

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

(2010) Stewart Factor et al.   PARKINSONISM & RELATED DISORDERS

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

(2009) R. A. Hodgson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Medical Treatment of Parkinson Disease

(2009) Mark Stacy   NEUROLOGIC CLINICS

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Adenosine A2Areceptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms

(2008) Liqun Yu et al.   ANNALS OF NEUROLOGY

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY

Levodopa for the Treatment of Parkinson's Disease

(2008) Peter A. LeWitt   NEW ENGLAND JOURNAL OF MEDICINE

Positron emission tomography analysis of [11C]KW‐6002 binding to human and rat adenosine A2Areceptors in the brain

(2008) D.J. Brooks et al.   SYNAPSE